These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 8854074)

  • 1. Tissue polypeptide-specific antigen in renal cell carcinoma.
    Höbarth K; Hallas A; Kramer G; Aulitzky W; Gomahr A; Steiner G; Marberger M
    Eur Urol; 1996; 30(1):89-95. PubMed ID: 8854074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue polypeptide specific antigen (TPS) as a tumor marker in renal cell carcinoma.
    Chang CH; Wu HC; Yen RF; Kao A; Lin CC; Lee CC
    Anticancer Res; 2002; 22(5):2949-50. PubMed ID: 12530023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating immune markers in advanced renal cell carcinoma during immunotherapy with interferon gamma.
    Höbarth K; Hallas A; Steiner G; Gomahr A; Aulitzky W; Marberger M
    Urol Res; 1996; 24(2):101-6. PubMed ID: 8740979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of cytokeratin-18-related tissue polypeptide-specific (TPS) antigen in Wilms tumor.
    Rebhandl W; Handisurya A; Memaran N; Felberbauer FX; Aberle J; Paya K; Strobl B; Horcher E
    Med Pediatr Oncol; 2001 Oct; 37(4):357-64. PubMed ID: 11568899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum ferritin as a clinical marker for renal cell carcinoma: influence of tumor volume.
    Partin AW; Criley SR; Steiner MS; Hsieh K; Simons JW; Lumadue J; Carter HB; Marshall FF
    Urology; 1995 Feb; 45(2):211-7. PubMed ID: 7855968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical evaluation of serum tissue polypeptide-specific antigen (TPS) in non-small cell lung cancer.
    Pujol JL; Cooper EH; Grenier J; Purves DA; Lehmann M; Ray P; Aouta MD; Bashir M; Godard P; Michel FB
    Eur J Cancer; 1994; 30A(12):1768-74. PubMed ID: 7880603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TPS in breast cancer--a comparative study with carcinoembryonic antigen and CA 15-3.
    van Dalen A
    Tumour Biol; 1992; 13(1-2):10-7. PubMed ID: 1589693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer.
    Sliutz G; Tempfer C; Kainz C; Mustafa G; Gitsch G; Koelbl H; Biegelmayer C
    Anticancer Res; 1995; 15(3):1127-9. PubMed ID: 7645936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer.
    Gaarenstroom KN; Bonfrer JM; Kenter GG; Korse CM; Hart AA; Trimbos JB; Helmerhorst TJ
    Cancer; 1995 Sep; 76(5):807-13. PubMed ID: 8625184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokeratin tumor marker levels in bronchial washing in the diagnosis of lung cancer.
    Trevisani L; Putinati S; Sartori S; Abbasciano V; Bagni B
    Chest; 1996 Jan; 109(1):104-8. PubMed ID: 8549168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).
    Wechsel HW; Petri E; Bichler KH; Feil G
    Anticancer Res; 1999; 19(4A):2583-90. PubMed ID: 10470199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma.
    Hamberg AP; Korse CM; Bonfrer JM; de Gast GC
    Melanoma Res; 2003 Feb; 13(1):45-9. PubMed ID: 12569284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of CYFRA 21-1 and tissue polypeptide specific antigen (TPS) for detecting nasopharyngeal carcinoma.
    Tai CJ; Liu FY; Liang JA; Yang SN; Tsai MH; Kao CH
    Anticancer Res; 2002; 22(6B):3793-6. PubMed ID: 12552995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib.
    Terakawa T; Miyake H; Kusuda Y; Fujisawa M
    Urol Oncol; 2013 May; 31(4):493-8. PubMed ID: 21478036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue polypeptide-specific antigen and CA 125 as serum tumor markers in ovarian carcinoma.
    Shabana A; Onsrud M
    Tumour Biol; 1994; 15(6):361-7. PubMed ID: 7997808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative high levels of serum vascular endothelial growth factor are a prognostic marker for poor outcome after surgical treatment of renal cell carcinoma.
    Guðbrandsdottir G; Hjelle KM; Frugård J; Bostad L; Aarstad HJ; Beisland C
    Scand J Urol; 2015; 49(5):388-94. PubMed ID: 25773545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High YKL-40 is associated with poor survival in patients with renal cell carcinoma: a novel independent prognostic marker.
    Väänänen T; Kallio J; Vuolteenaho K; Ojala A; Luukkaala T; Hämäläinen M; Tammela T; Kellokumpu-Lehtinen PL; Moilanen E
    Scand J Urol; 2017 Oct; 51(5):367-372. PubMed ID: 28644702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma.
    Sato K; Tsuchiya N; Sasaki R; Shimoda N; Satoh S; Ogawa O; Kato T
    Jpn J Cancer Res; 1999 Aug; 90(8):874-9. PubMed ID: 10543260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum basic fetoprotein in patients with renal cell carcinoma.
    Gohji K; Ishii M; Nagata H; Matsumoto O; Kamidono S
    Cancer; 1990 Mar; 65(6):1405-11. PubMed ID: 1689608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.